Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT06541990
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- HARMONY — BEHAVIORALA psychoeducational intervention for patients with HCC
- Enhanced usual care — OTHERA supportive care resource guide
Study Details
This study aims to refine and pilot test HARMONY, a psychoeducational intervention for patients with newly diagnosed hepatocellular carcinoma (HCC).
Key Dates
- Start date
- Oct 28, 2024
- Status verified
- Aug 2025
- Primary completion
- Jun 30, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: HARMONYHARMONY is a psychoeducational intervention that consists of three one-on-one coaching sessions and a structured session workbook.
- Active Comparator: Enhanced usual careThe enhanced usual care condition consists of a curated list of supportive care services for patients with HCC.
Primary Outcome Measure
Feasibility: study enrollment rate [ Time Frame: 10 weeks ]
Central Contacts
- Kelsey Lau-Min617-724-4000
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Kelsey Lau-Min, MD, MSCE (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
By condition
By specialty
By research site
Related Studies
- SIRT With Tremelimumab and Durvalumab for Resectable HCCPHASE1 · Recruiting · Jiping Wang, MD, PhD · Los Angeles, California
- A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisPHASE2 · Recruiting · Genentech, Inc. · Tucson, Arizona
- Dose-defining Study of Tirapazamine Combined With Embolization in Liver CancerPHASE1/PHASE2 · Recruiting · Teclison Ltd. · Palo Alto, California
- Combination of TATE and PD-1 Inhibitor in Liver CancerPHASE2 · Recruiting · Teclison Ltd. · Orange, California